Prospera Financial Services Inc Takes Position in Axon Enterprise, Inc $AXON

Prospera Financial Services Inc acquired a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,251 shares of the biotechnology company’s stock, valued at approximately $8,487,000.

A number of other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after purchasing an additional 185,571 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Axon Enterprise by 15.9% in the 1st quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock valued at $675,812,000 after buying an additional 175,890 shares in the last quarter. Westfield Capital Management Co. LP increased its holdings in Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after buying an additional 212,931 shares during the last quarter. Northern Trust Corp raised its position in Axon Enterprise by 1.2% during the first quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock valued at $381,692,000 after acquiring an additional 8,794 shares in the last quarter. Finally, Jennison Associates LLC lifted its stake in Axon Enterprise by 23,203.7% in the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock valued at $322,961,000 after acquiring an additional 611,418 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Up 2.6%

Axon Enterprise stock opened at $602.51 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. Axon Enterprise, Inc has a fifty-two week low of $469.24 and a fifty-two week high of $885.91. The firm has a fifty day moving average price of $719.61 and a two-hundred day moving average price of $736.04. The firm has a market cap of $47.30 billion, a price-to-earnings ratio of 148.77, a P/E/G ratio of 29.49 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). The business had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company’s revenue for the quarter was up 30.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.45 earnings per share. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total value of $75,254.00. Following the transaction, the director directly owned 1,416 shares of the company’s stock, valued at $1,065,596.64. The trade was a 6.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Jennifer H. Mak sold 77 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $760.00, for a total value of $58,520.00. Following the transaction, the chief accounting officer owned 15,003 shares of the company’s stock, valued at approximately $11,402,280. This trade represents a 0.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 59,932 shares of company stock worth $45,115,616. Insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Raymond James Financial restated an “outperform” rating and set a $855.00 price target (up previously from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Wall Street Zen cut shares of Axon Enterprise from a “hold” rating to a “sell” rating in a report on Saturday. Barclays cut their target price on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a report on Thursday. Northland Securities set a $800.00 price target on Axon Enterprise in a research report on Tuesday, August 5th. Finally, Cowen reissued a “buy” rating on shares of Axon Enterprise in a report on Wednesday. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $810.71.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.